Arbutus Biopharma Corp
ABUS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.20
KIRA · Stoqly’s AI analyst, in plain words
- Arbutus Biopharma Corp had $14.1M of revenue in fiscal 2025, up 128.2% on the year before. Over five years, revenue changed +15.3% a year on average.
- Its operating margin was −271.0%, up 965.8 pts: of every 100 in sales, about −271 is left after running the business.
- Arbutus Biopharma Corp lost $33.5M in fiscal 2025.
- Free cash flow was −$39.6M in fiscal 2025, −281.5% of revenue.
- Arbutus Biopharma Corp has $91.5M more cash than debt.
Market cap
$829M
P/E
5.3x
Revenue
$14.1M
Net income
−$33.5M
Free cash flow
−$39.6M
Operating margin
−271.0%
Arbutus Biopharma Corp in 30 seconds · fiscal 2025
Are sales growing?
+128.2%
Yes. Sales grew 128.2% last year.
Does it make a profit?
−237.9%
No. It lost money last year.
Does profit turn into cash?
−281.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
5.3x
One share costs 5.3 times its yearly profit per share.
What Arbutus Biopharma Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Arbutus Biopharma Corp
- CIK
- 0001447028
Arbutus Biopharma Corp · ABUS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Revenue growth | 58.9% | 255.1% | −53.5% | −66.0% | 128.2% |
| Operating margin | −669.1% | −167.8% | −430.5% | −1,236.7% | −271.0% |
| Net income | −$76.2M | −$69.5M | −$72.8M | −$69.9M | −$33.5M |
| Net margin | −693.9% | −178.0% | −401.6% | −1,133.0% | −237.9% |
| Diluted EPS | −$0.83 | −$0.46 | −$0.44 | −$0.38 | −$0.17 |
| Cash | |||||
| Cash from operations | −$67.5M | −$35.4M | −$85.9M | −$64.9M | −$39.6M |
| Capital expenditure | $0.8M | $0.5M | $1.0M | $0.2M | $0.0M |
| Free cash flow | −$68.3M | −$35.9M | −$86.9M | −$65.0M | −$39.6M |
| FCF margin | −622.0% | −91.9% | −479.3% | −1,053.8% | −281.5% |
| Share count change | 40.1% | 42.1% | 10.0% | 11.8% | 3.2% |
| Debt and strength | |||||
| Cash and short-term investments | $155M | $147M | $126M | $123M | $91.5M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $169M | $137M | $106M | $97.4M | $76.6M |
| Current ratio | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Interest coverage | −25.7x | −37.9x | −170.2x | −557.1x | −393.4x |
| Returns and quality | |||||
| Return on capital | −411.3% | — | — | — | — |
| Return on equity | −56.2% | −45.4% | −60.0% | −68.8% | −38.5% |
| Return on tangible equity | −52.2% | −50.8% | −68.7% | −71.8% | −43.7% |
| Piotroski F-score | 4 | 3 | 1 | 2 | 3 |
| Altman Z'' | −10.6 | −15.9 | −24.6 | −28.7 | −39.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arbutus Biopharma Corp · ABUS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.20 a share, the company is worth $829M: 5.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001447028). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.